| Project/Area Number |
24K10440
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Toyo University |
|---|
Principal Investigator |
モハメッド シェイク 東洋大学, バイオ・ナノエレクトロニクス研究センター, 研究助手 (50708609)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
菅 理江 埼玉医科大学, 医学部, 准教授 (10342685)
廣澤 成美 埼玉医科大学, 医学部, 准教授 (40327060)
水木 徹 東洋大学, バイオ・ナノエレクトロニクス研究センター, 研究助手 (80408997)
|
|---|
| Project Period (FY) |
2024-04-01 – 2027-03-31
|
| Project Status |
Granted (Fiscal Year 2024)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2026: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2025: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2024: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | Nano DDS / Glioblastoma / Gene Editing / CasMINI / Blood Brain Barrier |
|---|
| Outline of Research at the Start |
Glioblastoma is the most aggressive type of high-grade brain tumor with high mortality rates, for which CRISPR-cas gene editing technology could be a promising treatment option. We aim to utilize this technology, specifically targeted to brain tumors, for a superior treatment outcome.
|
